Skip to content
value.today

Neuraxis, Inc.

NRXS
$95 Mmarket cap on Oct 13, 2026
Compare
World rank
#18,885
Revenue
$4 M
For year ending December-2025
Net income
$-8 M
-218.5% margin
SEC filing
Employees
24
As of December 31, 2025
SEC filing

Neuraxis, Inc. in brief

Neuraxis, Inc. is a listed company in the Medical Devices industry, based in Carmel, Indiana, USA. Its market value was $95 M on 13 October 2026, which makes it the 18,885th largest listed company in the world and the 3,534th largest in the USA on this site. In the year to December 2025 it had sales of $4 M and a net loss of $8 M. It employs about 24 people and Brian Carrico is its chief executive. By market, the largest shares of its 2025 sales came from CALIFORNIA (25%), OHIO (16%) and MASSACHUSETTS (7%). Its shares trade under the symbol NRXS (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Neuraxis, Inc.

Neuraxis, Inc. is a first-to-market growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. With several indications in the market and additional clinical trials of Percutaneous Electrical Nerve Field Stimulation (PENFS) in multiple pediatric and adult conditions underway, we are focused on unmet GI healthcare needs in children and adults. We are dedicated to advancing science with our proprietary IB-Stim® therapy, based on our PENFS technology, which was developed internally by the Company. We believe that superior science and evidence-based research are necessary for adoption by the medical and scientific community. Additional clinical trials of PENFS in multiple pediatric and adult conditions are underway, focused on unmet healthcare needs in children and adults. See “Our Pipeline” for more information.

From the company's annual report filed with the US SEC: read the report

Neuraxis, Inc. timeline

3 events, 2022–2025
  1. 2022
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2023
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 11 August 2023; shares registered for exchange trading on 8 August 2023.
  5. 2025
  6. 💰
    Record revenue of $4 million
    FY2025, the highest of the 4 years on record.

Events of Neuraxis, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
14.6×
Price / book
28.1×
Free cash flow yield
-6.8%
Net margin (TTM)
-185.2%
Operating margin
-219.3%
Return on equity
-356.2%
Liabilities / assets
46.9%
Net debt
$-0M
Revenue growth
+32.7%
R&D / revenue
13.7%
Revenue per employee
$149 K
Profit per employee
$-325 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2022: revenue $3M, net income $-5M$3MFY22Fiscal year ending Dec 2023: revenue $2M, net income $-15M$2MFY23Fiscal year ending Dec 2024: revenue $3M, net income $-8M$3MFY24Fiscal year ending Dec 2025: revenue $4M, net income $-8M$4MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$4M+32.7%$-8M$-8M-218.5%
Dec 2024$3M+9.3%$-7M$-8M-306.3%
Dec 2023$2M-8.2%$-7M$-15M-594.7%
Dec 2022$3M—$-3M$-5M-178.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-6M$0M$-6M$-0.95—
Dec 2024$-6M$0M$-6M$-1.22—
Dec 2023$-7M$0M$-7M$-4.50—
Dec 2022$-2M$0M$-2M$-2.77—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$7M
Net income, trailing 12 months
$-12M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-1M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-2M$1MMar ’25Three months to Jun 2025: revenue $1M, net income $-2M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-2M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-2M$1MDec ’25Three months to Mar 2026: revenue $2M, net income $-2M$2MMar ’26Three months to Jun 2026: revenue $2M, net income $-2M$2MJun ’26Three months to Sep 2026: revenue $2M, net income $-7M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (+150.6% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Neuraxis, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$4 M
Operating income
$-8 M
Net income
$-8 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$6 M
Total liabilities
$3 M
Total equity
$3 M

As of December-2025

Top 40 institutional investors in Neuraxis, Inc.#

As of Sep 30, 2026
40 institutions held 2.6 M shares (about 18.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 15.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Neuraxis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Rosalind Advisors, Inc.548,123+40,068 (+7.89%)3.86%$4 MNov 16, 2026
2AIGH Capital Management LLC540,292+20,354 (+3.91%)3.81%$4 MNov 2, 2026
3Vanguard Capital Management LLC341,952+6,159 (+1.83%)2.41%$3 MNov 13, 2026
4Money Concepts Capital Corp235,674+7,645 (+3.35%)1.66%$2 MNov 6, 2026
5Renaissance Technologies LLC156,300-13,100 (-7.73%)1.10%$1 MNov 12, 2026
6Geode Capital Management, LLC90,999-5,362 (-5.56%)0.64%$1 MNov 6, 2026
7Parsons Capital Management Inc/ri90,807-27,001 (-22.92%)0.64%$1 MOct 28, 2026
8Eddie Patel Inc79,542+19,778 (+33.09%)0.56%$1 MNov 2, 2026
9BlackRock, Inc.60,125+1,473 (+2.51%)0.42%$0 MNov 13, 2026
10Vanguard Fiduciary Trust Co50,996-8,696 (-14.57%)0.36%$0 MNov 13, 2026
11State Street Corp47,737+3,500 (+7.91%)0.34%$0 MNov 12, 2026
12Centiva Capital, LP36,960-566 (-1.51%)0.26%$0 MNov 13, 2026
13T3 Companies, LLC27,200New0.19%$0 MOct 22, 2026
14Northern Trust Corp23,0830 (0.00%)0.16%$0 MNov 16, 2026
15Susquehanna International Group, LLP21,775New0.15%$0 MNov 16, 2026
16Elevation Point Wealth Partners, LLC21,000+6,700 (+46.85%)0.15%$0 MNov 5, 2026
17Prelude Capital Management, LLC19,107New0.13%$0 MNov 16, 2026
18Citadel Advisors LLC18,363-66,690 (-78.41%)0.13%$0 MNov 16, 2026
19Bridgeway Capital Management, LLC16,724-276 (-1.62%)0.12%$0 MNov 16, 2026
20Empowered Funds, LLC16,724New0.12%$0 MNov 13, 2026
21Marshall Wace, LLP16,383-112,372 (-87.28%)0.12%$0 MNov 13, 2026
22Vestmark Advisory Solutions, Inc.16,000+1,700 (+11.89%)0.11%$0 MNov 16, 2026
23UBS Group AG15,430-20,145 (-56.63%)0.11%$0 MNov 10, 2026
24Wealthcare Advisory Partners LLC15,1880 (0.00%)0.11%$0 MOct 21, 2026
25HRT Financial LP14,188-134 (-0.94%)0.10%$0 MNov 13, 2026
Show all 40: investors 26 to 40
Institutional investors 26 to 40 in Neuraxis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Occudo Quantitative Strategies LP12,765-1,409 (-9.94%)0.09%$0 MNov 16, 2026
27Jane Street Group, LLC11,864New0.08%$0 MNov 12, 2026
28LPL Financial LLC10,0000 (0.00%)0.07%$0 MNov 6, 2026
29Morgan Stanley5,8020 (0.00%)0.04%$0 MNov 13, 2026
30Vanguard Global Advisers, LLC5,226New0.04%$0 MNov 13, 2026
31Ascentis Independent Advisors1,990New0.01%$0 MNov 3, 2026
32Jones Financial Companies Lllp1,176New0.01%$0 MNov 13, 2026
33Tower Research Capital LLC (TRC)1,111-48 (-4.14%)0.01%$0 MNov 16, 2026
34Ulland Investment Advisors, LLC1,0000 (0.00%)0.01%$0 MOct 13, 2026
35Royal Bank Of Canada345-155 (-31.00%)0.00%$0 MNov 16, 2026
36Simplex Trading, LLC255New0.00%$0 MNov 4, 2026
37Steward Partners Investment Advisory, LLC150New0.00%$0 MNov 13, 2026
38Caitong International Asset Management Co., Ltd54+40 (+285.71%)0.00%$0 MOct 29, 2026
39FMR LLC100 (0.00%)0.00%$0 MNov 10, 2026
40Barclays PLC3-401 (-99.26%)0.00%$0 MNov 6, 2026

Mutual funds holding Neuraxis, Inc.#

11 funds hold shares worth $3 M (about 3.2% of the company). Since their previous reports 8 added shares and 1 sold, buying $1 M net.
Mutual funds holding Neuraxis, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.222,869$2 M1.6%<0.01%+77%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.99,792$1 M0.70%<0.01%−0.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC43,388$0 M0.31%<0.01%+2.2%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors29,351$0 M0.21%0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC17,000$0 M0.12%0.08%+240%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,872$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC12,505$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.7,463$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,169$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,947$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC282$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Neuraxis, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.4 M
9 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$1.4 M
open market only
Insiders on file
10
since
$1.0 M-$1.8 M$0Dec 2023: bought $0 (0 trades), sold $198 (1 trades)Dec 23Apr 2025: bought $31 K (1 trades), sold $0 (0 trades)AprJul 2025: bought $800 K (1 trades), sold $1.8 M (2 trades)JulDec 2025: bought $1.0 M (1 trades), sold $0 (0 trades)DecFeb 2026: bought $383 K (2 trades), sold $0 (0 trades)FebApr 2026: bought $32 K (3 trades), sold $0 (0 trades)AprOct 2026: bought $12 K (3 trades), sold $0 (0 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Neuraxis, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Thomas Joeseph CarricoCRO, CCO, CPOBuy+328$4.840$2 K199,673Form 4
filed Brian Allen CarricoChief Executive Officer, DirectorBuy+268$4.840$1 K227,604Form 4
filed Timothy Robert HenrichsChief Financial OfficerBuy+1,937$4.840$9 K9,530Form 4
filed Adrian MirandaCMO, SVP Science & TechGrant or award+199,106——199,106Form 4
filed Brian Allen CarricoChief Executive Officer, DirectorGrant or award+199,188——227,336Form 4
filed Thomas Joeseph CarricoCRO, CCO, CPOGrant or award+193,678——199,345Form 4
filed Kristin A. FergeDirectorGrant or award+31,134$6.280$196 K67,072Form 4
filed Jane Elizabeth KeyserDirectorGrant or award+26,073$6.280$164 K72,408Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Neuraxis, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
455,871
4.3% of shares · 4.37 days to cover
Buybacks, Q1 2023
$0.1M
Q1 2024
Shares sold short, last 24 reportsAll stocks →
Neuraxis, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2023Q1 2024$0.1M

Fails to deliver

  • : 5,548 shares at $6.72
  • : 435 shares at $7.40
  • : 685 shares at $5.70
  • : 33 shares at $5.75
  • : 279 shares at $5.74

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Neuraxis, Inc. scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in growth (2 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 13, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median28.1×Price to book 28.1× against Medical Devices's median of 2.5×.
    • ✗Price to sales below its peers' median14.6×Price to sales 14.6× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-6.8%Free cash flow is -6.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 4
    • ✓Revenue grew in the newest year32.7%Revenue up 32.7% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years10.0%10.0% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median10.0%10.0% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.95 vs -1.22Diluted EPS -0.95 in fiscal 2025 against -1.22 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-219.3%-219.3% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-285.2%-285.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-219.3%-219.3% in fiscal 2025 against -125.7% in 2022.
  • Financial health2 of 4
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.05 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-111.9×Operating income -111.9 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone2.02Z-score 2.02 (grey zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year31.3%Diluted shares up 31.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Neuraxis, Inc.'s statements, beside the median of Medical Devices.

Neuraxis, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-219.3%-8.2%
Net margin-218.5%-10.4%
Return on equity-285.2%-16.8%
Revenue growth, 3 years a year10.0%10.8%
Revenue growth32.7%10.4%
Free cash flow margin-181.0%-1.9%

3of 8on the Piotroski tests of financial strength

  • Net loss of $8 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$6 million.
  • The share count rose 31.3% in the year.
  • Operating income covers the interest bill only -111.9 times.

Neuraxis, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Neuraxis, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Revenue3,5692,6862,4602,685
Cost of revenue563362303297
Gross profit3,0062,3242,1572,388
Research and development494434r169226
Selling and marketing2,2801,469r324411
General and administrative8,0637,578r8,3285,123
Operating income−7,830−7,157−6,664−3,372
Interest expense and finance costs74174476319
Other non-operating income (expense)29−1,085−7,962−1,408
Net income attributable to shareholders−7,801−8,242−14,627−4,780
Earnings per share, basic-0.95-1.22-4.50-2.77
Earnings per share, diluted-0.95-1.22-4.50-2.77
Shares, weighted average (basic)9.16.93.32.0
Shares, weighted average (diluted)9.16.93.32.0
Balance sheet
Cash and cash equivalents4,9653,69779254
Receivables19624573174
Inventory257442148
Other current assets315280700.7
Current assets5,7334,266243477
Property, plant and equipment76908988
Right-of-use (leased) assets26228570101
Other intangible assets2759710878
Total assets6,4044,7585091,481
Accounts payable1395971,2041,592
Customer deposits29337559
Current liabilities2,7922,4331,8866,978
Lease liabilities (non-current)2032562776
Non-current liabilities2132562776
Total liabilities3,0052,6901,9137,054
Retained earnings−64,600−56,800−48,558−33,931
Shareholders' equity3,3992,068−1,403−5,574
Total liabilities and equity6,4044,7585091,481
Shares outstanding117.06.52.0
Cash-flow statement
Depreciation and amortization60384137
Share-based compensation597227027
Cash from operating activities−6,433−6,098−6,694−2,298
Capital expenditure−31−28−31−1.4
Intangible assets bought−100—−41−60
Cash from investing activities−131−28−72−61
Shares issued7,728—4,847—
Cash from financing activities7,8329,7446,5912,292
Change in cash1,2683,618−175−67
Report10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Neuraxis, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

  • All other States$1 M35%
  • CALIFORNIA$1 M25%
  • OHIO$1 M16%
  • MASSACHUSETTS$0 M7.4%
  • ILLINOIS$0 M6.2%
  • WISCONSIN$0 M6.0%
  • FLORIDA$0 M4.0%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Neuraxis, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$936 K
Brian Carrico
Other top executives, average
$652 K
the CEO earned 1.4× this
$100 invested is now
$72
Neuraxis, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Brian Carrico$936 K$1.3 M$652 K$72
2024Brian Carrico$578 K$578 K$460 K$37
2023Brian Carrico$839 K$839 K$367 K$42

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Neuraxis, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 7 · Agreement ended 1 · New debt 2 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5

Neuraxis, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersMaterial agreementAgreement ended8-K
Shareholder vote8-K
Material agreement8-K
Material agreementNew debt8-K
Results announced8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Unregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreementNew debt8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 19, 2026

H-1B hiring at Neuraxis, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $72 K a year.

Certified, FY2026
1
#1,960 among companies on value.today
Worker positions
1
Median wage offered
$72 K
a year, full-time
Applications filed
1
Neuraxis, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Staff AccountantAccountants and Auditors1$72 K

Where: Carmel, IN 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as NeurAxis, Inc.

How Neuraxis, Inc. compares in Medical Devices

  • Market cap$95 M · higher than 35% of 142
  • Revenue$4 M · higher than 12% of 155
  • Net margin-185.2% · higher than 8% of 144
  • Revenue growth32.7% · higher than 85% of 104
  • Price / sales14.6× · lower than 5% of 96
  • Price / book28.1× · lower than 3% of 99
  • FCF yield-6.8% · higher than 35% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Neuraxis, Inc.🇺🇸$95 M—-185.2%+32.7%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 13, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Neuraxis, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Neuraxis, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Neuraxis, Inc.? Suggest a correction